FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to a combination of a type II anti-CD20 antibody and an anti-Bcl-2 active agent for treating cancer, first, CD20 expressing cancer, wherein the above type II anti-CD20 antibody is a humanised B-Lyl antibody and the above active agent is a Bcl-2 protein binding inhibitor and thereby destroys the Bad/Bcl-2 complex with the IC50 anti-Bcl-2 inhibitory activity of 1 mcM or less, as well as to using the type II anti-CD20 antibody for producing a medical drug applicable for treating cancer, first, CD20 expressing cancer, in a combination with the anti-Bcl-2 active agent.
EFFECT: group of inventions in effective in treating cancer, first, CD20 expressing cancer, in a combination with the anti-Bcl-2 active agent.
10 cl, 3 dwg, 2 tbl, 4 ex
